Semaglutide for non-diabetic CKD: review

A 2026 systematic review and meta-analysis pooled three studies covering 430 people to ask a narrow question: what happens to the kidneys and blood pressure of adults who take semaglutide for obesity but do not have diabetes, when they also have chronic kidney disease or hypertension. The review reported lower body mass index, more patients reaching a systolic blood pressure under 130 mmHg, and preserved kidney filtration rate across the included studies, and it concluded the drug was effective and well tolerated in this group^[1]. The evidence base behind that conclusion is small, and the long-term part of the title is doing more work than the data supports.

What the review actually pooled

The authors screened 580 records and included just three: a randomised controlled trial, a real-world observational study in patients on dialysis, and a larger post hoc trial analysis. Together they covered 430 participants. The review followed PRISMA reporting guidelines, which require a documented search strategy and a risk-of-bias assessment, and the authors reported no publication bias^[1]. The outcomes it tracked were body mass index, systolic blood pressure, estimated glomerular filtration rate (a measure of how well the kidneys filter blood, usually shortened to eGFR), and albuminuria (protein leaking into the urine, an early marker of kidney damage).

On the numbers, body mass index fell across the studies, with mean reductions ranging from 1.5% to 18.3%. The share of patients reaching a systolic blood pressure under 130 mmHg ranged from 12.5% to 20.6%. And the proportion maintaining an eGFR above 30 ml/min/1.73m2 rose from baseline in all three studies^[1]. Read carefully, that is a signal of stability and modest improvement in surrogate markers, not a demonstration that semaglutide prevents kidney failure in this population.

The one dedicated non-diabetic trial

The strongest single piece of evidence for the exact population in the title is a randomised, double-blind, placebo-controlled trial of 101 adults with overweight or obesity and chronic kidney disease but without diabetes. Over 24 weeks, semaglutide 2.4 mg weekly cut urine albumin-to-creatinine ratio by 52.1% compared with placebo and lowered body weight and systolic blood pressure^[2]. That albuminuria result is meaningful because protein in the urine tracks with kidney-disease progression. But the trial ran for 24 weeks in 101 people, which is a proof-of-concept, not a long-term outcomes study.

Where the durable kidney evidence comes from

The strongest long-term kidney data for semaglutide sits in a different population. The FLOW trial randomised 3,533 adults with type-2 diabetes and chronic kidney disease and reported a 24% lower risk of a composite kidney-failure endpoint over a median 3.4 years (hazard ratio 0.76, 95% CI 0.66 to 0.88)^[3]. That is the hard-outcome evidence, and it is in people with diabetes. The systematic review borrows confidence from trials like this one while studying a group the trial did not enrol.

The closest large dataset in non-diabetic patients is the SELECT trial, which enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. SELECT reported a 20% reduction in major adverse cardiovascular events (hazard ratio 0.80, 95% CI 0.72 to 0.90)^[4]. Its kidney findings were a secondary analysis showing slower eGFR decline and lower albuminuria, not a primary kidney-failure result. So even the biggest non-diabetic trial answers the cardiovascular question directly and the kidney question only at the edges.

What this does not tell us

Three studies and 430 people cannot settle long-term safety. The dialysis study was observational, the dedicated non-diabetic trial lasted 24 weeks, and the post hoc analysis was not designed around this population. Pooling outcomes measured differently across studies of different designs is a real limitation, and surrogate markers like eGFR and albuminuria are not the same as kidney failure, dialysis, or death. The review is best read as an early synthesis that points toward a hypothesis worth a dedicated trial, not as a green light.

Semaglutide also carries a known side-effect profile that does not disappear because the indication is kidney-focused. Gastrointestinal effects are the most common reason people stop, and rapid weight loss raises the risk of gallbladder events. Those trade-offs are covered on our semaglutide side-effects overview. Semaglutide is a prescription-only medicine across the EU, UK, and US, and it is not approved specifically for non-diabetic chronic kidney disease in any of those jurisdictions. If you have kidney disease or high blood pressure and are weighing this drug, that decision belongs with a nephrologist or your prescribing clinician, not with a pooled estimate from three small studies.